Nintedanib (Ofev) and Pirfenidone (Esbriet)

Type: drug

Status: FDA Approved

Developer: Boehringer Ingelheim (Nintedanib), Genentech/Roche (Pirfenidone)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026